Browse Studies — Arctuva

Phase 1

Combinations of Sacituzumab Govitecan Plus Enfortumab Vedotin and Pembrolizumab for Metastatic Urothelial Carcinoma: the Double Antibody Drug Conjugate (DAD) and Double Antibody Drug Conjugate With Immunotherapy (DAD-IO) Phase I/II Trial

Phase I of this research study will assess what doses of Sacituzumab Govitecan and Enfortumab Vedotin can be safely combined in the treatment of metastatic uro…

Urothelial CancerMetastatic Urothelial CarcinomaMetastatic Urothelial Carcinoma of the Renal Pelvis and Ureter+1 more

Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT04724018

Phase 2

Phase II Open-Label Multi-Cohort Study Evaluating CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Patients With Advanced Chemorefractory Colorectal, Pancreatic, or Other Solid Cancers

This phase II trial tests how well CPI-613 (devimistat) in combination with hydroxychloroquine (HCQ) and 5-fluorouracil (5-FU) or gemcitabine works in patients…

Advanced Biliary Tract CarcinomaAdvanced Colorectal CarcinomaAdvanced Gastroesophageal Junction Adenocarcinoma+30 more

Observational

An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy

The purpose of this study is to understand the metabolism of cancers involving the kidney, including renal cell carcinomas and urothelial cell carcinomas, and …

Kidney CancerRenal Cell CarcinomaClear Cell Carcinoma+9 more

Estimated

~$10 – $6,250

University of Texas Southwestern Medical CenterNCT04623502

Phase 2

A Modular, Open Label, Randomized Phase II/III Trial to Assess Efficacy of Combining sEphB4-HSA (EphrinB2 Inhibitor) With Immunotherapy Regimens in Patients With EphrinB2-High Solid Tumors

Patients with solid tumors that have high expression levels of EphrinB2 are treated with regimens that include EphrinB2 inhibitor, sEphB4-HSA. The primary obje…

Muscle-Invasive Bladder CarcinomaMetastatic Urothelial Carcinoma

Estimated

~$10 – $8,750

Vasgene Therapeutics, IncNCT06493552